High-frequency, low-dose rituximab achieved ~85% peripheral CLL clearance within 1 hour and ~34% nodal reduction in 1 week, with macrophage phagocytosis and complement as dominant mechanisms.

Rituximab is a chimeric mouse–human monoclonal antibody (mAb) that targets the B-cell surface marker CD20 with high affinity. CD20 expression spans the developmental stages from the pre-B cell until ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...